Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR3 over exp |
Therapy | Atezolizumab + Rogaratinib |
Indication/Tumor Type | transitional cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR3 over exp | transitional cell carcinoma | sensitive | Atezolizumab + Rogaratinib | Phase I | Actionable | In a Phase Ib trial (FORT-2), Tecentriq (atezolizumab) and Rogaratinib (BAY 1163877) combined therapy demonstrated safety and led to an objective response rate (ORR) of 43% (16/37, 5 complete and 11 partial responses), disease control rate of 65% (24/37), median progression-free survival of 6.1 mo, median overall survival of 12.0 mo, and ORR of 54% (14/26) at the RP2D of 600mg in cisplatin-ineligible patients with metastatic urothelial cancer with FGFR1 or FGFR3 overexpression (PMID: 39298147; NCT03473756). | 39298147 |
PubMed Id | Reference Title | Details |
---|---|---|
(39298147) | Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial. | Full reference... |